187 related articles for article (PubMed ID: 37662928)
1. Integrated transcriptomics, proteomics and metabolomics-based analysis uncover TAM2-associated glycolysis and pyruvate metabolic remodeling in pancreatic cancer.
Li X; Du Y; Jiang W; Dong S; Li W; Tang H; Yi J; Zhou W; Zhang H
Front Immunol; 2023; 14():1170223. PubMed ID: 37662928
[TBL] [Abstract][Full Text] [Related]
2. Integration of transcriptomics, proteomics, and metabolomics data to reveal HER2-associated metabolic heterogeneity in gastric cancer with response to immunotherapy and neoadjuvant chemotherapy.
Yuan Q; Deng D; Pan C; Ren J; Wei T; Wu Z; Zhang B; Li S; Yin P; Shang D
Front Immunol; 2022; 13():951137. PubMed ID: 35990657
[TBL] [Abstract][Full Text] [Related]
3. Integration of Single-Cell RNA Sequencing and Bulk RNA Sequencing Reveals That TAM2-Driven Genes Affect Immunotherapeutic Response and Prognosis in Pancreatic Cancer.
Du Y; Dong S; Jiang W; Li M; Li W; Li X; Zhou W
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628967
[TBL] [Abstract][Full Text] [Related]
4. A novel immune checkpoint score system for prognostic evaluation in pancreatic adenocarcinoma.
Chen Y; Lin X; Zou X; Qian Y; Liu Y; Wang R; Wang X; Yu X; Liu C; Cheng H
BMC Gastroenterol; 2023 Apr; 23(1):113. PubMed ID: 37024802
[TBL] [Abstract][Full Text] [Related]
5. Molecular subtypes based on cuproptosis-related genes and tumor microenvironment infiltration characteristics in pancreatic adenocarcinoma.
Li J; Yin J; Li W; Wang H; Ni B
Cancer Cell Int; 2023 Jan; 23(1):7. PubMed ID: 36647100
[TBL] [Abstract][Full Text] [Related]
6. An immunogenic cell death-related gene expression signature in predicting prognosis of pancreatic ductal adenocarcinoma.
Wang X; Ren T; Liao C; Xie Y; Cao J
BMC Genomics; 2024 Feb; 25(1):205. PubMed ID: 38395786
[TBL] [Abstract][Full Text] [Related]
7. A prospective prognostic signature for pancreatic adenocarcinoma based on ubiquitination-related mRNA-lncRNA with experimental validation in vitro and vivo.
Wang Z; Yuan Q; Chen X; Luo F; Shi X; Guo F; Ren J; Li S; Shang D
Funct Integr Genomics; 2023 Aug; 23(3):263. PubMed ID: 37540295
[TBL] [Abstract][Full Text] [Related]
8. High WFDC3 gene expression is associated with poor prognosis and reduced immune cells infiltration in pancreatic adenocarcinoma: A study using the TCGA database and bioinformatics analysis.
Wu W; Wang J; Hu Z; Zhao Y; Wang X; Bai N; Chen L; Gao P
Medicine (Baltimore); 2023 Oct; 102(42):e35595. PubMed ID: 37861515
[TBL] [Abstract][Full Text] [Related]
9. Development and Validation of an Inflammatory Response-Related Gene Signature for Predicting the Prognosis of Pancreatic Adenocarcinoma.
Deng ZL; Zhou DZ; Cao SJ; Li Q; Zhang JF; Xie H
Inflammation; 2022 Aug; 45(4):1732-1751. PubMed ID: 35322324
[TBL] [Abstract][Full Text] [Related]
10. Alteration in glycolytic/cholesterogenic gene expression is associated with bladder cancer prognosis and immune cell infiltration.
Zhang Y; Zhu B; Cai Y; Zhu S; Zhao H; Ying X; Jiang C; Zeng J
BMC Cancer; 2022 Jan; 22(1):2. PubMed ID: 34980012
[TBL] [Abstract][Full Text] [Related]
11. Mitophagy-mediated molecular subtypes depict the hallmarks of the tumour metabolism and guide precision chemotherapy in pancreatic adenocarcinoma.
Chen H; Zhang J; Sun X; Wang Y; Qian Y
Front Cell Dev Biol; 2022; 10():901207. PubMed ID: 35938160
[No Abstract] [Full Text] [Related]
12. Comprehensive Analysis of m6A RNA Methylation Regulators and the Immune Microenvironment to Aid Immunotherapy in Pancreatic Cancer.
Guo Y; Wang R; Li J; Song Y; Min J; Zhao T; Hua L; Shi J; Zhang C; Ma P; Yang C; Zhu L; Gan D; Li S; Liu X; Su H
Front Immunol; 2021; 12():769425. PubMed ID: 34804059
[TBL] [Abstract][Full Text] [Related]
13. System analysis based on the pyroptosis-related genes identifies GSDMC as a novel therapy target for pancreatic adenocarcinoma.
Yan C; Niu Y; Li F; Zhao W; Ma L
J Transl Med; 2022 Oct; 20(1):455. PubMed ID: 36199146
[TBL] [Abstract][Full Text] [Related]
14. Tumor mutation burden-related long non-coding RNAs is predictor for prognosis and immune response in pancreatic cancer.
Wang C; Wang Z; Zhao Y; Jia R
BMC Gastroenterol; 2022 Nov; 22(1):495. PubMed ID: 36451085
[TBL] [Abstract][Full Text] [Related]
15. Screening and validating the core biomarkers in patients with pancreatic ductal adenocarcinoma.
Li Y; Zhu YY; Dai GP; Wu DJ; Gao ZZ; Zhang L; Fan YH
Math Biosci Eng; 2019 Nov; 17(1):910-927. PubMed ID: 31731384
[TBL] [Abstract][Full Text] [Related]
16. Construction and comprehensive analysis of a novel prognostic signature associated with pyroptosis molecular subtypes in patients with pancreatic adenocarcinoma.
Huang Q; Peng X; Li Q; Zhu J; Xue J; Jiang H
Front Immunol; 2023; 14():1111494. PubMed ID: 36817451
[TBL] [Abstract][Full Text] [Related]
17. Integrate analysis of the promote function of Cell division cycle-associated protein family to pancreatic adenocarcinoma.
Xing C; Wang Z; Zhu Y; Zhang C; Liu M; Hu X; Chen W; Du Y
Int J Med Sci; 2021; 18(3):672-684. PubMed ID: 33437202
[No Abstract] [Full Text] [Related]
18. CXCL10 is a prognostic marker for pancreatic adenocarcinoma and tumor microenvironment remodeling.
Nie Y; Liu C; Liu Q; Zhu X
BMC Cancer; 2023 Feb; 23(1):150. PubMed ID: 36782176
[TBL] [Abstract][Full Text] [Related]
19. Transmembrane Protein 170B is a Prognostic Biomarker and Associated With Immune Infiltrates in Pancreatic Adenocarcinoma.
Zhang Z; Shang J; Dai Z; Yao Y; Shi Y; Zhong D; Liang Y; Lai C; Yang Q; Feng T; Huang X
Front Genet; 2022; 13():848391. PubMed ID: 35601487
[No Abstract] [Full Text] [Related]
20.
Kuang W; Wang X; Ding J; Li J; Ji M; Chen W; Wang L; Yang P
Front Immunol; 2022; 13():805311. PubMed ID: 35154122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
